Phospho-EPB41 (Tyr660/418) Antibody

What is EPB41 and what is the significance of its Tyr660/418 phosphorylation?

EPB41, also known as protein 4.1R, is a membrane-cytoskeleton adaptor protein encoded by the EPB41 gene. It serves as a key component of the erythroid membrane skeleton that regulates red cell morphology and mechanical stability . EPB41 contains four main functional domains, with the N-terminal 30 kDa membrane binding domain (MBD or FERM domain) mediating interactions with various proteins in erythroid and non-erythroid cells .

The phosphorylation at tyrosine residue 660 (or 418, depending on the isoform) significantly impacts protein function. Specifically, Y660 phosphorylation is known to disturb the spectrin/actin/4.1 complex formation . This post-translational modification can trigger morphological changes in red blood cells, potentially leading to the formation of spherocytes by disrupting the vertical links between the membrane and cytoskeleton .

Which experimental techniques can utilize Phospho-EPB41 (Tyr660/418) antibodies?

Phospho-EPB41 (Tyr660/418) antibodies are versatile tools applicable across multiple experimental platforms:

• Western Blotting (WB): Typically used at dilutions of 1:500-1:1000

• ELISA: Generally performed at dilutions of 1:100-1:1000

• Immunohistochemistry (IHC): Especially for paraffin-embedded sections

• Cell-Based Assays: Including colorimetric cell-based ELISA kits specifically designed for phosphorylated EPB41 detection

These techniques enable researchers to quantify and visualize the presence and distribution of phosphorylated EPB41 in various biological contexts.

What is the species reactivity profile of typical Phospho-EPB41 (Tyr660/418) antibodies?

Most commercially available Phospho-EPB41 (Tyr660/418) antibodies demonstrate reactivity against human and mouse samples . Some antibodies also show cross-reactivity with rat samples . This cross-species reactivity is valuable for comparative studies across different model organisms, though researchers should verify the specific reactivity of their chosen antibody for their experimental system.

How does EPB41 Tyr660/418 phosphorylation impact cellular morphology in erythrocytes?

Phosphorylation of EPB41 at Tyr660/418 has profound effects on erythrocyte morphology through multiple mechanisms:

• Disruption of Cytoskeletal Integrity: The Y660 phosphorylation specifically disturbs the spectrin/actin/4.1 complex, a critical structural element in erythrocyte membranes .

• Morphological Transition Pathway: Phosphoproteomic and morphological studies reveal that inhibition of protein tyrosine phosphatases (using orthovanadate treatment) induces phosphorylation of EPB41 at Y660, triggering a transition from normal discocytes to abnormal spherocytes .

• Sequential Morphological Changes: Time-lapse experiments demonstrate that EPB41 phosphorylation first induces echinocyte formation (cells with spiculated membranes) before progressing to spherocytes over approximately 20 hours of observation .

• Kinase Involvement: The phosphorylation appears to be regulated by specific kinases, including epidermal growth factor receptor (EGFR), as kinase inhibitors targeting these pathways can prevent the morphological changes associated with EPB41 phosphorylation .

This process represents a fundamental mechanism in diseases like hereditary elliptocytosis where red blood cell membrane integrity is compromised.

What experimental considerations are critical when using phospho-specific antibodies for EPB41 in cell signaling studies?

When employing Phospho-EPB41 (Tyr660/418) antibodies in cell signaling investigations, researchers should consider:

Sample Preparation Optimization:

• Phosphatase Inhibition: Include orthovanadate (OV) or similar phosphatase inhibitors in lysis buffers to preserve phosphorylation status .

• Extraction Conditions: For membrane proteins, optimal extraction requires buffers containing 8M urea, 2M thiourea, 0.5% SDS, and 10mM DTE to maintain protein solubility while preserving phosphorylation .

Validation Requirements:

• Specificity Controls: Verify antibody specificity using competing phosphopeptides versus non-phosphopeptides .

• Signal Confirmation: Antibodies detect endogenous levels of EPB41 only when phosphorylated at tyrosine 660/418, so appropriate positive and negative controls are essential .

Quantification Methodologies:

• Mass Spectrometry Correlation: Quantitative mass spectrometry can validate immunological detection of phosphorylation sites, with Class 1 phosphosites (localization probability >0.75) providing higher confidence .

• Statistical Analysis: Apply permutation-based multiple-testing analyses (false discovery rate ≤0.05) when analyzing differential phosphorylation .

What is the relationship between EPB41 phosphorylation and disease pathogenesis?

EPB41 phosphorylation has been implicated in multiple disease processes:

Hematological Disorders:

• Hereditary Elliptocytosis (HE-1): Mutations in the EPB41 gene, which can affect phosphorylation sites or their regulatory domains, lead to red blood cell membrane instability and elliptical deformation . A novel mutation (p.Trp704*) in the EPB41 gene was recently identified in a Korean patient with HE .

Cancer Biology:

• Hepatocellular Carcinoma (HCC): EPB41 functions as a tumor suppressor gene in hepatocellular carcinoma, with expression significantly decreased in HCC tissue specimens, especially in portal vein metastasis or intrahepatic metastasis .

• Tumor Growth Regulation: Xenograft models demonstrate that stable expression of EPB41 in HepG2 cells inhibits tumor growth, suggesting its phosphorylation status may influence cancer progression .

• Metastatic Potential: EPB41 impacts cancer cell growth, apoptosis, invasion, and metastasis through cytoskeletal reorganization, processes potentially regulated by its phosphorylation status .

Signal Transduction Aberrations:

• c-Myc Interaction: The EPB41 gene is regulated by c-Myc, with genetic polymorphisms (specifically rs157224) affecting this regulation and subsequently modifying HCC susceptibility .

What are the optimal protocols for detecting phosphorylated EPB41 in different sample types?

For Western Blotting:

For Phosphoproteomics Analysis:

• Digest samples with Lys-C (1:50 enzyme/protein) followed by trypsin gold (1:50)

• Enrich phosphopeptides using titanium dioxide (TiO₂) tips

• Analyze by LC-MS/MS on high-resolution instruments (e.g., Orbitrap Q-Exactive HF)

• Process data with specialized software (MaxQuant/Perseus) using appropriate statistical parameters (FDR=0.05)

How can researchers effectively differentiate between specific EPB41 phospho-isoforms?

Distinguishing between EPB41 phospho-isoforms requires careful methodological consideration:

Antibody Selection Strategy:

• Epitope Specificity: Select antibodies raised against the specific phospho-epitope of interest. For Tyr660/418, the epitope sequence N-I-Y(p)-I-R is commonly used as immunogen .

• Purification Method: Optimal antibodies undergo two-step purification - first with phosphopeptide affinity chromatography for positive selection, followed by non-phosphopeptide chromatography to remove non-phospho-specific antibodies .

Validation Approaches:

• Phosphatase Treatment: Treat duplicate samples with lambda phosphatase to confirm phospho-specificity .

• Competing Peptides: Pre-incubate antibody with phosphorylated versus non-phosphorylated peptides to confirm specificity .

• Knockout/Knockdown Controls: Use siRNA-mediated knockdown of EPB41 (siEPB41-1, siEPB41-2, siEPB41-3) to validate signal specificity .

Mass Spectrometry Confirmation:

• For definitive isoform identification, targeted mass spectrometry approaches can distinguish specific phosphorylation sites when multiple possibilities exist .

What are the methodological considerations when studying EPB41 phosphorylation dynamics in living cells?

Time-Resolved Imaging Approaches:

• Digital Holographic Microscopy (DHM): This label-free technique provides quantitative phase images to analyze morphological changes associated with EPB41 phosphorylation in real-time .

• Time-Lapse Parameters: For RBC studies, images should be acquired every 30 minutes for approximately 20 hours to capture the complete morphological transition sequence .

Experimental Design Considerations:

• Kinase/Phosphatase Modulation: Pre-treat cells with specific kinase inhibitors (e.g., PRT062607, bafetinib, or H89) before phosphatase inhibition to establish causality in phosphorylation cascades .

• Cell Preparation: For RBC studies, seed cells (80,000 per well) in Poly-L-ornithine-coated plates and centrifuge briefly (140g for 2 minutes) to ensure uniform cell distribution .

• Environmental Control: Maintain cells at 37°C with 5% CO₂ and high humidity during time-lapse experiments to prevent artifactual morphological changes .

Quantification Methods:

• Population Analysis: Calculate the spatial standard deviation of optical path difference (SD-OPD) .

• Single-Cell Phenotypic Analysis: Use software like CellProfiler to categorize cell morphologies (e.g., "discocytes," "echinocytes," "spherocytes") .

• Integrative Parameters: Area under the curve (AUC) analysis integrates information about cell behavior throughout the entire observation period .

How might targeting EPB41 phosphorylation be developed into therapeutic strategies?

Emerging research suggests several potential therapeutic directions targeting EPB41 phosphorylation:

Hematological Disorders:

• Kinase Inhibitors: Specific inhibitors targeting Lyn kinase (e.g., bafetinib) or Syk kinase (e.g., PRT062607) have demonstrated ability to prevent pathological phosphorylation of EPB41 and other membrane proteins, potentially preserving erythrocyte morphology in conditions like spherocytosis .

• PKA Modulation: Inhibitors such as H89 that target protein kinase A (PKA) pathways show promise in preventing OV-induced morphological changes, suggesting alternative therapeutic targets .

Cancer Therapeutics:

• EPB41 as Tumor Suppressor: Given EPB41's role as a tumor suppressor in HCC, therapies enhancing its expression or function may inhibit tumor growth . Xenograft studies confirm that stable EPB41 expression can reduce tumor growth in vivo .

• c-Myc Pathway Intersection: The interaction between c-Myc and EPB41 regulation offers potential targets for cancer therapy, especially in HCC where the rs157224 polymorphism affects this regulatory relationship .

Combinatorial Approaches:

• Targeting multiple phosphorylation sites simultaneously (both tyrosine and serine/threonine) may provide synergistic therapeutic effects, as demonstrated by the collaborative impact of different kinase inhibitors on cellular morphology .

What are the current technological limitations in studying EPB41 phosphorylation dynamics?

Despite significant advances, several challenges remain in studying EPB41 phosphorylation:

Technical Challenges:

• Temporal Resolution: Current phosphoproteomic methods provide snapshots rather than continuous measurement of phosphorylation dynamics .

• Spatial Organization: Most techniques cannot resolve the spatial distribution of phosphorylated EPB41 within subcellular compartments .

• Isoform Complexity: The EPB41 gene undergoes extensive alternative splicing, producing multiple isoforms ranging from 30 to 210 kDa, complicating phosphorylation analysis .

Methodological Limitations:

• Antibody Cross-Reactivity: Phospho-specific antibodies may recognize similar phospho-epitopes on related proteins, requiring careful validation .

• Phospho-Enrichment Bias: Current enrichment techniques may preferentially capture certain phosphopeptides while missing others, potentially skewing results .

• Mass Spectrometry Sensitivity: Low-abundance phosphorylation events may fall below detection thresholds of even advanced mass spectrometry approaches .

Future Technology Needs:

• Development of live-cell phosphorylation sensors for real-time monitoring

• Improved computational models to predict phosphorylation cascade effects

• Higher sensitivity mass spectrometry approaches for comprehensive phosphoproteome coverage

How does EPB41 phosphorylation interface with broader cellular signaling networks?

EPB41 phosphorylation exists within a complex signaling ecosystem:

Integrated Signaling Pathways:

• Kinase Networks: Network analysis reveals EPB41 phosphorylation connections to multiple kinase activities, including non-specific protein tyrosine kinases (YES1, LCK, SRC, FYN) and Lyn kinase (LYN) .

• Membrane Complex Formation: Phosphorylated EPB41 interacts with band 3–ankyrin complexes, connecting to flotillin-2 (FLOT2), aquaporin-1 (AQP1), receptor protein tyrosine kinase (EPHB4), and phosphatidylinositol pathways .

Cross-Regulatory Mechanisms:

• PKA-EGFR Interaction: While Y660 is expected to be phosphorylated by epidermal growth factor receptor (EGFR), studies show PKA can interact with EGFR, creating cross-talk between tyrosine and serine/threonine phosphorylation pathways .

• Spectrin/Actin Interactions: EPB41 phosphorylation regulates interactions with spectrin and actin, affecting cytoskeletal organization and membrane stability .

Disease-Specific Pathway Alterations:

• Cancer Signaling Rewiring: In cancers, EPB41 interacts with aldolase C (ALDOC), with inhibition of EPB41 expression increasing the release of ALDOC from EPB41-ALDOC complexes .

• Pathway Visualization: Network analysis tools (e.g., String-db.org) have identified clusters of proteins involved in EPB41-related complexes, providing visual representations of these signaling networks .